Shortly after departing from her role as Teva’s COO for US generics and biosimilars, Christine Baeder has been named as president of Apotex in the US. Meanwhile, Coherus Biosciences has announced a CFO transition and Amgen has made executive appointments to “accelerate innovation”.
Christine Baeder, the former senior vice president and chief operating officer for US generics and biosimilars at Teva who left the company recently, has now been revealed as the new president of Apotex in the US.
Describing Baeder as “a leading US pharmaceutical executive with over 20 years of experience in progressively senior roles in the...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
